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Abstract: Vitamin K plays a crucial role in blood coagulation, and hypercoagulability has been linked
to atherosclerosis-related vascular disease. We used the Mendelian randomization study design to
examine whether circulating vitamin K1 (phylloquinone) levels are associated with ischemic stroke.
Four single-nucleotide polymorphisms associated with vitamin K1 levels were used as instrumental
variables. Summary-level data for large artery atherosclerotic stroke (n = 4373 cases), small vessel
stroke (n = 5386 cases), cardioembolic stroke (n = 7193 cases), and any ischemic stroke (n = 34,217 cases
and 404,630 non-cases) were available from the MEGASTROKE consortium. Genetically-predicted
circulating vitamin K1 levels were associated with large artery atherosclerotic stroke but not with any
other subtypes or ischemic stroke as a whole. The odds ratios per genetically predicted one nmol/L
increase in natural log-transformed vitamin K1 levels were 1.31 (95% confidence interval (CI) 1.12–1.53;
p = 7.0 × 10−4) for large artery atherosclerotic stroke, 0.98 (95% CI 0.85–1.12; p = 0.73) for small vessel
stroke, 1.01 (95% CI 0.90–1.14; p = 0.84) for cardioembolic stroke, and 1.05 (95% CI 0.99–1.11; p = 0.11)
for any ischemic stroke. These findings indicate that genetic predisposition to higher circulating
vitamin K1 levels is associated with an increased risk of large artery atherosclerotic stroke.
Keywords: Mendelian randomization; single nucleotide polymorphisms; stroke; vitamin K1
1. Introduction
Vitamin K is a group of fat-soluble vitamins that occur in two natural active forms. Vitamin K1
(phylloquinone) is present predominantly in green leafy vegetables and plant oils and is the main form
of vitamin K in the Western diet [1,2]. Vitamin K2 (menaquinone) occurs in animal products (e.g., egg
yolks and butter) and fermented foods (e.g., cheese), and is synthesized by certain intestinal bacteria [2].
Vitamin K1 is preferentially accumulated in the liver, where it plays an essential role in the synthesis of
coagulation factors [3]. Warfarin, a commonly prescribed drug to control blood coagulation and to
reduce thrombotic events, is a vitamin K antagonist. Contrary to vitamin K1, vitamin K2 has a more
widespread distribution pattern [3] and is hypothesized to play a role in preventing cardiovascular
disease by inhibiting vascular calcification [2]. Whereas a high vitamin K1 intake has been shown to
increase arterial thrombosis tendency, vitamin K2 has been found to have the opposite effect [4].
Hypercoagulability tends to increase atherosclerosis and is linked to atherosclerosis-related
ischemic arterial disease [5]. High plasma vitamin K1 levels were found to be associated with an
increased prevalence of coronary artery calcification [6]. Thus, elevated circulating vitamin K1 levels,
due to a high dietary intake or genetic predisposition, might increase the risk of cardiovascular
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disease. Observational studies investigating the association between dietary vitamin K1 intake and
risk of cardiovascular disease are scarce and available studies show either no association or an inverse
association [7–10]. A limitation of the observational findings is the potential concern of residual
confounding, since a high vitamin K1 intake may reflect a healthy diet and lifestyle. Moreover, no
study examined whether the association of vitamin K1 intake with ischemic stroke differs by ischemic
stroke subtypes.
Mendelian randomization (MR) is a technique that uses genetic variants associated with
a modifiable (non-genetic) exposure of interest as proxy indicators (instrumental variables) for the
exposure to infer causality [11]. Genetic variants are randomly assorted at meiosis and are thus
less likely to be associated with potential confounding factors of the exposure-outcome relationship
(Figure 1). A recent MR study showed that genetically higher vitamin K1 levels were associated with
a significantly increased risk of coronary artery disease (odds ratio of 1.17 per 1 nmol/L increase
of natural log-transformed vitamin K1 levels) [12], which is usually caused by atherosclerosis. It is
unknown whether high circulating vitamin K1 levels increase the risk of large artery atherosclerotic
stroke (LAS), which share several modifiable risk factors (e.g., hypertension, high-density lipoprotein
cholesterol levels, and type 2 diabetes) [13–15] and non-modifiable genetic predisposition [16] with
coronary artery disease.
We conducted a two-sample MR study to test the hypothesis that high circulating vitamin K1 levels
are associated with an increased risk of LAS. We also examined the associations of genetically-predicted
vitamin K1 levels with small-vessel stroke (SVS), cardioembolic stroke (CES), and ischemic stroke as
a whole.
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Figure 1. Concept of a Mendelian randomization (MR) study. A genetic variant (or multiple genetic
variants in combination) associated with a modifiable risk factor, such as circulating vitamin K levels,
can be used as an instrumental variable to determine the association between the risk factor and the
outcome. The genetic variant used as an instrumental variable must (1) be robustly associated with the
risk factor under study, (2) not be associated with any confounding factors of the risk factor-outcome
relationship, and (3) affect the outcome through the risk factor under study and not through any
other causal pathway. The dashed lines represent potential associations between variables that would
represent violations of the Mendelian randomization assumptions.
2. Methods
2.1. Data Sources and SNP Selection
A genome-wide association study of 2138 individuals of European ancestry identified 11
single-nucleotide polym rphisms (SNPs) in five loci that were ass ciated with circulating vitamin K1
levels at p < 1 × 10−6 [17]. From each locus, we selected the SNP with the st ongest association (low st
p value) with vitamin K1 levels. On of the SNPs (rs964184 in ZNF259) is trongly associated with
cholesterol and triglycerid levels [18] and was excluded from the analyse t avoi pleiotropic bias.
Thus, four SNPs were used s instrumental variables for vitamin K1 levels (Table 1).
Summary-level data for the four vitamin K1-associated SNPs with ischemic stroke and its subtypes
were available from 438,847 European-descent individuals, including 34,217 cases of ischemic stroke,
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included in the MEGASTROKE consortium [19]. Subtyping of ischemic stroke was largely based on
the Trial of Org 10,172 in Acute Stroke Treatment criteria. Data on ischemic stroke subtypes were
available for 4373 LAS, 5386 SVS, and 7193 CES cases [19].
Table 1. Characteristics of the vitamin K1-associated single-nucleotide polymorphisms and their
associations with ischemic stroke subtypes.
Vitamin K1 LAS SVS CES
SNP NearbyGene Chr EA * β
† SE β ‡ SE β ‡ SE β ‡ SE
rs4645543 KCNK9 8 C 0.42 0.08 0.089 0.060 −0.081 0.052 −0.050 0.044
rs2108622 CYP4F2 19 T 0.16 0.03 0.015 0.029 −0.023 0.026 0.042 0.021
rs2192574 CTNAA2 2 C 0.28 0.06 0.110 0.037 0.050 0.035 0.002 0.029
rs4122275§ CDO1§ 5 G 0.68 0.17 0.220 0.156 −0.070 0.121 0.011 0.123
Abbreviations: CES, cardioembolic stroke; Chr, chromosome; EA, effect allele; LAS, large artery atherosclerotic
stroke; SE, standard error; SNP, single nucleotide polymorphism; SVS, small vessel stroke. * Allele associated with
higher vitamin K1 levels. † The β coefficient represents the change in vitamin K1 (ln-nmol/L) per additional copy of
the effect allele, and is adjusted for age, sex, and study-specific covariates (e.g., study site, population stratification
by principal components). ‡ Log odds ratio of stroke per additional copy of the effect allele. § The two SNPs in
this locus with the strongest association with vitamin K1 levels were not available in the stroke dataset. The third
strongest SNP (rs4122275) at this locus was available and used.
2.2. Statistical Analysis
The statistical analyses were conducted using the mrrobust package for Stata (StataCorp, College
Station, TX, USA) [20]. For each of the four SNPs, we computed an instrumental variable ratio
estimate by dividing the beta-coefficients (log odds ratio) for the SNP—stroke association by the beta
coefficient for the SNP—vitamin K1 association. An overall odds ratio across the four SNPs was
obtained by combining the ratio estimates using the inverse-variance weighted method (hereafter
referred to as standard MR analysis) [21]. As sensitivity analyses, we used the weighted median
method, which provides a valid estimate if at least 50% of weight comes from valid instrumental
variables, and MR-Egger methods, which can explore and adjust for pleiotropy [21]. All statistical tests
were two-sided, and considered statistically significant at a pre-specified p value below 0.05.
3. Results
Relationships of the vitamin K1-associated SNPs with ischemic stroke subtypes are shown in
Table 1. Genetically-predicted circulating vitamin K1 levels were positively associated with LAS
(Figure 2, Figures S1 and S2) but not with the other ischemic stroke subtypes or overall ischemic
stroke (Figure 2). In the standard MR analysis, the odds ratios per genetically-predicted one nmol/L
increase in natural log-transformed vitamin K1 levels were 1.31 (95% confidence interval (CI) 1.12–1.53;
p = 7.0 × 10−4) for LAS, 0.98 (95% CI 0.85–1.12; p = 0.73) for SVS, 1.01 (95% CI 0.90–1.14; p = 0.84) for
CES, and 1.05 (95% CI 0.99–1.11; p = 0.11) for any ischemic stroke (Figure 2). There was no heterogeneity
between individual SNPs associations with LAS (I2 = 0%; p = 0.57; Figure S1).
Results were similar in the sensitivity analyses using the weighted median and MR-Egger methods
but the CIs were broader, indicating lower power in these analyses compared to the inverse-variance
weighted analysis (Figure 2). The MR-Egger analysis revealed no evidence of directional pleiotropy in
the analysis of LAS (p = 0.52), SVS (p = 0.93), or any ischemic stroke (p = 0.20), but there was suggestive
evidence of directional pleiotropy in the analysis of CES (p = 0.04).
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We next searched the PhenoScanner database [22] for possible pleiotropic associations of
individual SNPs with risk factors for LAS. Associations of the vitamin K1-associated SNPs were
observed for rs4645543 with former smoking (p = 0.004), rs2108622 with diastolic blood pressure
(p = 0.015) and circulating vitamin E levels (p = 1.4 × 10−10; the vitamin K1-increasing allele is
associated with higher vitamin E levels), and rs2192574 with low-density lipoprotein cholesterol
(p = 0.02). In a sensitivity analysis removing these SNPs, the OR of LAS ranged from 1.22 (95% CI
1.00–1.48; p = 0.047) when excluding rs2192574, to 1.36 (95% CI 1.15–1.62; p = 4.4 × 10−4) when
excluding rs2108622.
4. Discussion
This study showed that genetically higher circulating vitamin K1 levels are associated with
an increased risk of LAS. This finding, along with results from previous MR and cohort studies
showing positive associations of circulating vitamin K1 levels with coronary artery disease [12] and
calcification [6], suggests that high vitamin K1 levels may increase the risk of atherosclerotic-related
vascular disease.
We observed no association of genetically-predicted vitamin K1 levels with other stroke subtypes
or with overall ischemi str ke. Th lack of association with overall ischemic stroke is consistent with
results of previous observational studies showing no association between d etary vitamin K1 intake
and overall risk f ischemic stroke [7,9,10]. Results of vitamin K1 intake in relation to LAS and other
subtypes were not available in other observational studies.
Previous studies reported that genetic variants related to increased thrombosis increases risk of
both LVS and CES, i.e., all subtypes with a presumed thromboembolic basis [23]. Therefore, in some
aspects, an association between genetically higher vitamin K1 levels and CES might have been expected.
We cannot exclude that we may have overlooked a weak association between genetically higher vitamin
K1 levels and CES. However, an alternative explanation is that vitamin K1 may increase LAS risk
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by other mechanisms, including atherogenesis itself, and vitamin K1 has been related to increased
arterial calcification [6]. Vitamin K is required for the conversion of coagulation factors II, VII, IX, and X
into their biologically active forms. In a study of 600 ischemic stroke cases and 600 population-based
controls, elevated factor VII antigen plasma levels were positively associated with risk of LAS but not
CES [24].
An important strength of the present study is that confounding and reverse causality was
mitigated through the use of genetic variants as proxies for circulating vitamin K1 levels. Two
of the main potential biases that can affect the results of an MR study are population stratification
(i.e., confounding by ancestry) and pleiotropy. Our findings are unlikely confounded by population
stratification because the analyses included individuals of European ancestry only. Furthermore, our
results were consistent in sensitivity analyses and there was no evidence that pleiotropy affected the
results. However, when assessing pleiotropic associations of individual SNPs, we found that the SNP
in the CYP4F2 gene was associated with higher vitamin E levels. Although the role of vitamin E in
LAS is unknown, our findings became somewhat stronger after exclusion of that SNP.
A limitation of this MR study is that the vitamin K1-asociated SNPs did not achieve conventional
genome-wide significance (p < 5 × 10−8), probably due to the relatively small genome-wide association
study [17]. This raises the possibility of false positives (i.e., type I error), and it cannot be ruled out
that the SNPs associated with vitamin K1 levels are proxies for other causal SNPs. The standard MR
approach assumes a linear association between the exposure and outcome. We could not examine
if the association between vitamin K1 levels and LAS is non-linear and if there is a threshold effect.
Another shortcoming is that we were unable to assess the association between circulating vitamin
K2 (menaquinone) levels and ischemic stroke, as no SNPs has, to the best of our knowledge, been
identified to be associated with vitamin K2 levels.
5. Conclusions
The findings of this MR study indicate that genetic predisposition to higher circulating vitamin
K1 levels may be associated with an increased risk of LAS but no other ischemic stroke subtypes or
with overall ischemic stroke. This finding warrant replication by further studies.
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